A Study of the Safety and PK of PCS6422 (Eniluracil) with Capecitabine in Patients with Advanced, Refractory GI Tract Tumors
This study is an open label, multicenter study in patients who have advanced, relapsed refractory GI cancer or are not relapsed/refractory but are intolerant to other therapies who, in the judgment of investigators, are candidates for fluoropyrimidine monotherapy.
Advanced Cancer|Refractory Cancer|Tumor Gastric
DRUG: PCS6422 and capecitabine
Number of participants with dose limiting toxicities (DLT) and incidence of adverse events as assessed by CTCAE v5.0, Frequency, duration, and severity of DLTs and adverse events (AEs), ~6 months|Maximum Plasma Concentration (Cmax) of capecitabine, To evaluate the Maximum Plasma Concentration (Cmax) of capecitabine, ~14 days
QTc effect of PCS6422, To evaluate the effect of PCS6422 on QTc, ~6 months|Maximum Plasma Concentration (Cmax) of PCS6422, To evaluate the Maximum Plasma Concentration (Cmax) of PCS6422, ~14 days|Number of participants with Adverse Events of Special Interest (AESI), Frequency, duration and severity of AESIs, ~6 months
This study is an open label, multicenter study in patients who have advanced, relapsed refractory GI cancer or are not relapsed/refractory but are intolerant to other therapies who, in the judgment of investigators, are candidates for fluoropyrimidine monotherapy.